Is implant placement under or above the chest muscle best in immediate breast reconstruction?
| ISRCTN | ISRCTN10081873 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10081873 |
| IRAS number | 279460 |
| Secondary identifying numbers | IRAS 279460, CPMS 46954 |
- Submission date
- 25/08/2020
- Registration date
- 12/01/2021
- Last edited
- 10/01/2023
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Surgery
Plain English Summary
Background and study aims
A mastectomy is an operation to remove a breast. A mastectomy may be recommended if cancer is in a large area of the breast; cancer has spread throughout the breast, or the breast is full of pre-cancerous cells. Breast reconstruction is an operation to make a replacement for the tissue removed during a mastectomy. It's often done at the same time as a mastectomy, but it can be done at a later date.
There are two ways in which implants can be placed during implant-based breast reconstruction; the implants can be placed under the chest muscle (a subpectoral implant) or placed on top of the chest muscle (pre-pectoral implant). Both are standard procedures commonly performed across the UK but currently here is currently no good evidence which implant procedure is best for patients
This study will test whether subpectoral or pre-pectoral implant placement improves women’s satisfaction with the outcome of their reconstruction in a small trial, to test if it is feasible to carry out a larger trial later.
Who can participate?
Women aged 18 years or older, who require a mastectomy for breast cancer or risk-reduction.
What does the study involve?
Participants will be randomly allocated into two equal groups. One group will have a subpectoral implant-based breast reconstruction and the other will have a pre-pectoral implant-based breast reconstruction. We also want to capture how information about the study is given to patients. This will help us understand how research studies are explained to people and if there are any improvements we can make.
What are the possible benefits and risks of participating?
This study will not benefit patients directly but the information provided will help to improve the future management of patients who undergo implant breast reconstructive surgery. Also, some people enjoy being part of a research study because of the close contact with research staff and their opportunity to share their opinions and experiences of their condition and treatments.
Risks- There should be no additional risks to routine NHS practice of either implant-based reconstruction procedure, and neither are new or experimental. The participant will have the same risks as anyone having immediate implant-based reconstruction
Where is the study run from?
Southmead Hospital (UK)
When is the study starting and how long is it expected to run for?
January 2020 to August 2023
Who is funding the study?
National Institute for Health Research (NIHR) (UK)
Who is the main contact?
Shelley Potter, shelley.potter@bristol.ac.uk
Dr Kirsty Roberts, kirsty.roberts@bristol.ac.uk
Contact information
Scientific
Southmead Hospital
Bristol
BS10 5NB
United Kingdom
 ORCID ID |
0000-0002-6977-312X |
|---|---|
| Phone | +44 (0)117 9287218 |
| shelley.potter@bristol.ac.uk |
Public
Population Health Sciences
Bristol Medical School
Canynge Hall
39 Whatley Rd
Bristol
BS8 2PS
United Kingdom
| ORCID ID |
0000-0003-0765-3752 |
|---|---|
| Phone | +44 (0)7989 981816 |
| kirsty.roberts@bristol.ac.uk |
Study information
| Study design | Pragmatic two-arm external pilot randomised controlled trial with QuinteT Recruitment Intervention (QRI) and economic scoping |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Quality of life |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | Is subpectoral or pre-pectoral implant placement Best in immediate BReAst reconstruction? The Best-BRA Pilot Trial |
| Study acronym | Best-BRA pilot |
| Study hypothesis | Pre-pectoral implant based breast reconstruction (IBBR), a ‘muscle sparing’ technique which involves the wrapping of the implant in mesh and placing it on top rather than underneath the pectoralis muscle may improve patient outcome compared to subpectoral (under the muscle) IBBR and it is becoming increasingly popular. There is however, a lack of high-quality evidence to support the effectiveness of either of these techniques. Before a large-scale trial is conducted, we first need to address whether surgeons will recruit patients to a randomised study comparing two approaches to IBBR and whether patients will consent to be randomised and agree to receive their allocated treatment. |
| Ethics approval(s) | Approved 12/01/2021, Wales REC 6 (Floor 4, Institute of Life Science 2, Swansea University, Swansea, SA2 8PP; +44 (0)7920 565 664; Wales.REC6@wales.nhs.uk ), ref: 20/WA/0338 |
| Condition | Implant-based breast reconstruction following mastectomy for breast cancer |
| Intervention | Women who require a mastectomy for either breast cancer or risk reduction and elect to have an IBRR will be recruited and randomised 1:1 for either a subpectoral or pre-pectoral implant reconstruction with mesh. Patients will then receive standard care as per clinical guidelines and be followed-up for 12 months. A QRI will be used to identify recruitment challenges and optimise recruitment to the trial. Best-BRA will assess the feasibility of a future, multi-centre randomised controlled trial to determine the most clinically effective and most cost-effective IBBR technique. Randomisation- The randomisation sequence will be generated by the Bristol Medical School’s REDCap database randomisation system. Participants will only be randomised after eligibility and consent have been confirmed. Patients will be randomly allocated to the techniques in a 1:1 ratio stratified by hospital. Randomisation within blocks of varying size will prevent large imbalances in the number of patients in each treatment arm. Randomisation will occur at the final clinic visit prior to admission for surgery. Access to the allocation will be by a web-based system and the allocation will be concealed until the patient has been logged into the system and a study ID number generated so ensuring that judgements about eligibility are made without knowledge of the next allocation (allocation concealment). The unit of randomisation will be the patient. Those women having bilateral mastectomy and IBBR will have the same procedure on each side (i.e. either pre-pectoral or subpectoral) within the study. The surgeon will be informed of the patient’s treatment allocation following randomisation to allow them to plan theatre lists and ensure sufficient operating time is available. |
| Intervention type | Procedure/Surgery |
| Primary outcome measure | Assessed throughout the duration of the trial using screening logs: 1. Recruitment into trial (number of sites recruiting; proportion of eligible women approached that are randomised, women recruited per site per month) 2. Adherence to trial allocation by comparing number of women allocated to trial intervention vs. their actual reconstruction (i.e pre-pec or subpectoral IBBR) 3. Completion rates measured by overall data completeness (% missing data) |
| Secondary outcome measures | 1. Satisfaction with breasts using the validated BREAST-Q questionnaire at 12 months 2. Surgical complications, in particular implant loss, infection, re-admission and reoperation measured using patient records at 3 and 12 months 3. Need for additional surgery to the reconstruction or the contralateral breast measured using patient records at 12 months 4. Pain scores assessed using a visual analogue scale (VAS) at 24 hours and 1 week 5. Objective cosmetic outcome at 12 months assessed using routinely collected patient photographs 6. EQ-5D-5L health-related quality of life score at 12 months 7. Wellbeing (ICECAP-A) score at 12 months 8. Patient-reported outcome domains included in the breast reconstruction core outcome set including physical well-being (chest); emotional well-being; and animation assessed using appropriate subscales of the BREAST-Q at 12 months 9. Cost-effectiveness of pre-pectoral and subpectoral IBBR assessed by micro-costing the two procedures. Data will be gathered from electronic notes/medical records as well as routine data |
| Overall study start date | 01/01/2020 |
| Overall study end date | 31/08/2023 |
| Reason abandoned (if study stopped) | Participant recruitment issue |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Female |
| Target number of participants | 100 |
| Total final enrolment | 11 |
| Participant inclusion criteria | 1. Aged 18 years or above 2. Require a mastectomy for breast cancer or risk-reduction 3. Elect to undergo immediate IBBR 4. Considered eligible for either pre or subpectoral reconstruction by the surgical team |
| Participant exclusion criteria | 1. Had a delayed reconstruction 2. Has had revision breast reconstruction surgery |
| Recruitment start date | 26/07/2021 |
| Recruitment end date | 31/01/2023 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Bristol
BS10 5NB
United Kingdom
Hillfield Road
Hemel Hempstead
HP2 4AD
United Kingdom
Wilsons Lane
Coventry
CV6 6NY
United Kingdom
Sponsor information
Hospital/treatment centre
Southmead Hospital
Southmead Road
Westbury-On-Trym
Bristol
BS10 5NB
England
United Kingdom
| Phone | +44 (0)117 4149330 |
|---|---|
| ResearchSponsor@nbt.nhs.uk | |
| Website | http://www.nbt.nhs.uk/ |
"ROR" |
https://ror.org/036x6gt55 |
Funders
Funder type
Government
Government organisation / National government
- Alternative name(s)
- National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
- Location
- United Kingdom
No information available
Results and Publications
| Intention to publish date | 01/02/2023 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Stored in repository |
| Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study will be stored in a publically available repository. Anonymous data sets will be made ‘open data’ following publication and stored in the University of Bristol’s Research Data Storage Facility (RDSF). (http://www.bristol.ac.uk/acrc/research-data-storage-facility) |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | 30/11/2021 | 24/01/2022 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
10/01/2023: The trial was closed early due to recruitment issues. The final enrolment number has been added.
24/01/2022: The following changes have been made:
1. The recruitment end date has been changed from 01/10/2022 to 31/01/2023.
2. The overall trial end date has been changed from 01/02/2022 to 31/08/2023 and the plain English summary has been updated to reflect this change.
3. Publication reference added.
26/07/2021: The following changes have been made:
1. The recruitment start date has been changed from 01/09/2021 to 26/07/2021.
2. Hemel Hempstead Hospital and University Hospitals Coventry and Warwickshire NHS Trust have been added to the trial participating centres.
19/07/2021: The recruitment start date was changed from 01/07/2021 to 01/09/2021.
15/06/2021: The recruitment start date was changed from 01/06/2021 to 01/07/2021.
19/04/2021: The recruitment start date was changed from 01/04/2021 to 01/06/2021.
03/09/2020: Trial’s existence confirmed by National Institute for Health Research (NIHR).
